Tanios S. Bekaii-Saab, MD, FACP | Authors

January 22, 2023

An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.

January 16, 2023

The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.

January 09, 2023

Elle Charnisky, a patient with HER2+ metastatic colorectal cancer, and Deanne Griffie, a nurse practitioner, share advice for patients and caregivers living with HER2+ mCRC.

January 09, 2023

Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.

January 04, 2023

Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.

January 04, 2023

Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.

December 28, 2022

Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.

December 28, 2022

Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.

December 21, 2022

John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.

December 21, 2022

A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.